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ABSTRACT 
 
 
Stem cell research has been a controversial topic for a long time with strong effects on 
society.  Misinformation about the subject seriously complicates the issue. Stem cells are 
undifferentiated or ‘blank’ cells of a multi-cellular organism that are capable of developing into 
many different cell types that perform different functions, and thus they show medical potential 
for treating various diseases.  In this project, various types of stem cells are discussed, along with 
how they have been used to benefit society.  Also discussed were their ethical and legal issues. 
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PROJECT OBJECTIVES 
 
 
The intention of this IQP was to investigate the controversial topic of stem cells as an 
example of the effects of technology on society.  Information was provided on the various kinds 
of stem cells and their applications to help dispel myths about their use and potentials. The effect 
of this new stem cell technology on society was investigated in four such chapters. The first 
chapter discussed the various types of stem cells, how they are classified, and their potencies. 
Chapter-2 describes various examples of how stem cells have been used medically, and their 
future prospects.  Chapter-3 discussed the ethical issues of stem cells, and noted the views of the 
five major religions on this very controversial topic. Chapter-4 examined the laws that govern 
these cells in the U.S. and other countries.  Finally the authors provided their own conclusions on 
the use of stem cells. 
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Chapter-1:  Stem Cell Types and Sources 
Nirali Parekh 
 	  
Although stem cells were first discovered in animals decades ago, the contentious topic 
of stem cells is not very old.  Since the journal Science declared advances in stem cell research to 
be the “breakthrough of the year” (Chamany, 2004), the field has continued to expand, catching 
the interest of businessmen, policy-makers, ethicists, and many more scientists.   Stem cells are 
long lived cells with the ability to form new tissues, and are the basis of the new field of 
regenerative medicine.  But when referring to “stem cells”, most people mistake all stem cells to 
be embryonic stem cells.  Actually there are many different types of cells with various levels of 
potency, so the purpose of this chapter is to introduce the reader to the various stem cell types. 
All types of stem cells have three common properties, 1) the capability to renew and 
divide for an extensive time period, 2) unspecialization, and 3) the ability to give rise to more 
specialized cells (Stem Cell Basic, 2005).  Stem cells are unspecialized, meaning that they do not 
participate in the functions performed by the cells they give rise to.  For example, hematopoietic 
stem cells do not transport oxygen through the bloodstream, although they give rise to the blood 
cells that do. When unspecialized stem cells give rise to specialized cells, the process is termed 
“differentiation”.  Every cell in the body was initially a stem cell which then developed into a 
specific functional cell like the heart, kidney, or muscle cells. Unlike many specialized cells, 
stem cells can replicate themselves numerous times over an individual’s entire life span.  A 
symmetric division, where the daughter cells carry the exact chromosome copy of the mother 
cells, occurs about 10 times in the life of a specialized cell. But when stem cells divide, they 
retain the ability to generate another unspecialized cell. Thus, stem cells can be considered to be 
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“immortal”. This type of stem cell division is termed asymmetric division, where one of the 
daughter cells becomes a new stem cell and the other cell becomes specialized (Stem Cells… 
2001).  	  	  
Stem Cell Classification by Potency 
Stem cells are usually divided into four main categories that describe the extent to which 
they can differentiate (Figure-1).  The first type is totipotent cells, which have the ability to give 
rise any kind of cell, including any cell in the body or extra-embryonic tissue like the placenta.  
Only newly fertilized zygotes and cells through the 8-cell stage are totipotent.  After a few days 
of fertilization, the totipotent cells start to specialize. The first stage of differentiation occurs as 
two cell layers are formed in the blastocyst. The inner cell mass of the blastocyst are the 
pluripotent cells (embryonic stem cells), which have the ability to differentiate into almost all 
kinds of cells in the body that arise from the three primary germ layers, but they cannot form 
placenta. The pluripotent cells then give rise to multipotent cells, which have a more limited 
range of differentiation.  This type of stem cells is limited to forming several types of related 
cells.  An example of a multipotent cell would be a hematopoietic stem cell, which forms all the 
cellular components of blood.  Then there are the unipotent cells, which can give rise only to one 
particular type of cell, and cannot regenerate indefinitely.  Unipotent cells develop into their 
specified and final cell type. An example of this might be a skin stem cell which forms only skin 
epithelium. 	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Figure-1:  Diagram of Various Stem Cell Potencies.  Shown are the 
various levels of stem cells from totipotent cells to unipotent.  (Keller, 2005) 
 	  
Stem Cell Classification by Source 
Another way to classify stem cells is by source.  As mentioned above, embryonic stem 
cells are isolated from the inner cell mass of a blastocyst embryo.  These cells are pluripotent, 
and because they destroy the embryo to obtain them are ethically controversial.  However, stem 
cells are found not only in developing embryos but also in the fetus umbilical cord blood, the 
placenta, and many adult tissues.  By far, adult stem cells (ASCs) are the most widely 
researched, as some of them (hematopoietic stem cells) have been used for decades to treat 
various forms of blood cell cancers.  Hematopoietic stem cells (HSCs) (Frequently…2004) are 
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the precursors of all mature red and white blood cells. Other adult stem cell types can be found in 
the brain, blood, cornea, retina, heart, intestines, and several other areas (Weiss, 2005). 
 
Adult Stem Cells 
Adult stem cells are isolated from adult tissues.  These cells are rare in the body, so are 
hard to isolate.  They are also more difficult to grow than ES cells.  But because they are 
ethically less controversial, scientists hope to use them to treat diseases whenever possible.  
Table-I shows the various types of adult stem cells, some of which will be discussed below. 
 
Table-I:  List of Adult Stem Cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Stem Cell Basics, 2005. 
 
Research in the field of adult stem cells has given us much insight into what could be 
done with these cell lines, such as controlling and protecting vital organs from inflammatory and 
destructive autoimmune reactions (van Laar and Tyndall, 2006), treatment of cancer (Weiss, 
2005), and their possible use in the treatment of several other debilitating disorders.  The 
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problem with adult stem cells is they are limited in their usage. They are rare in the body, are 
hard to identify and isolate, are hard to grow, and are limited in their ability to differentiate. 
 
 
Hematopoietic Stem Cells 
Blood cell replacement through bone marrow transplantation is one of the best 
characterized applications of stem cells, and has been used to treat blood disorders and blood 
cancers.	  	  Hematopoietic stem cells (HSCs) are traditionally obtained from bone marrow, but are 
also present in umbilical cord blood, an especially rich source.  Cord HSCs have the advantage 
of being more primitive than bone marrow-derived HSCs, and therefore are less likely to be 
rejected by the patient.  Umbilical cord HSCs have been used for transplantation to reconstitute 
blood in patients exposed to radiation or chemotherapy.  They have also been used to treat some 
types of genetic diseases, transplantation of umbilical cord blood cells can give patients a new 
blood forming system that can carry genetically corrected cells (Frequently, 2004). These 
therapies will be described in more detail in Chapter 2. 
 
Mesenchymal Stem Cells 
Another type of stem cell found in bone marrow is the mesenchymal stem cell (MSC). 
MSCs are multipotent, and can form bone, muscle, fat, and cartilage (Glossary, 2004). MSCs are 
also involved in repairing bone and cartilage. Once these cells divide, their progeny become 
committed to one particular function characteristic of a specific tissue (e.g. cartilage) (Caplan, 
1991). 
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Neural Stem Cells 
Another type of adult stem cell is the neural stem cell (NSC).  These cells can be isolated 
from adult brain tissue and grown in culture media (Frequently, 2004).  Earlier dogma stated that 
brain and spinal cord were incapable of regenerating, but this dogma has now been overturned.  
Figure-2 shows a diagram of the pathway for forming neural stem cells.  Multi-potent stem cells 
form neural progenitor cells that differentiate into committed neural progenitor cells.  Then the 
committed cells differentiate into functional neurons (Gage, 2000). “The term ‘neural stem cell’ 
is used loosely to describe cells that (i) can generate neural tissue or are derived from the nervous 
system, (ii) have some capacity for self-renewal, and (iii) can give rise to cells other than 
themselves through asymmetric cell division” (Gage, 2000).  Adult NSCs were first isolated in 
1989 (Temple, 1989), and later research by Clas Johansson showed that new neurons are being 
continuously generated in specific areas of the adult nervous system, apparently from adult 
multi-potent stem cells (Johansson et al., 1999).  Rats with spinal cord injuries were shown to 
have increased ependymal cell proliferation. Ependymal cells give rise to cells that proliferate 
rapidly and that generate neurons. This data lead the researchers to believe that these ependymal 
cells were in fact neural stem cells, and are involved in the process of repairing central nervous 
system injuries (Johansson et al., 1999). 
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Figure-2:  Diagram of Neural Stem Cell 
Formation and Differentiation.  Neural 
progenitor cells form from multi-potent stem 
cells.  The progenitor cells form committed 
progenitors that differentiate into neurons 
(Gage, 2000) 
 
 
 
 
 
 
In the adult brain, neurogenesis (the generation of new neurons) occurs in just two 
regions: 1) the subventricular zone lining the lateral ventricles, and 2) the subgranular zone 
(Bjorklund and Lindvall, 2000). These findings show that the brain has a latent capacity for self-
repair, although it appears to be severely limited (Bjorklund and Lindvall, 2000).  NSCs located 
in the central nervous system are limited in their mobility and accessibility, however they have 
been found to initiate and perform repairs (Johansson et al, 1999).  If scientists can determine 
how to maintain a cell line of these NSCs, many degenerative brain diseases could be stopped 
and perhaps reversed.  
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Renal Stem Cells 
Another example of adult stem cells is the renal stem cell (stem cells from the kidney).  
These cells have the potential for treating a variety of kidney disorders; however, we are still not 
completely sure if they exist (Watorek and Klinger, 2006).  A significant amount of data points 
to their existence, so they may have uses in treating kidney failure, renal diseases, and cancer of 
the kidney (Watorek and Klinger, 2006).  To determine if renal stem cells could generate the cell 
types found in the kidney, researchers examined the “differentiation potential of metanephric 
mesenchymal cells isolated on the first day of kidney development” (Oliver et al., 2002). The 
cells were examined and found to be “kidney-specific mesenchymal cells” that could indeed 
differentiate into specific cell lines found in the kidney, suggesting that these stem cells were 
specific to the kidney organ (Oliver et al, 2002).  
 
 
Embryonic Stem Cells 
ES cells are pluripotent, so they have the ability to become any cell type in the adult 
body, making ES cells a primary target for medical research. ES cells are easier to isolate and 
grow to large quantities than adult stem cells.  But they are ethically controversial because they 
are isolated from the inner cell mass of a 5 day old blastocyst, which destroys the embryo during 
the isolation process. 
Human ES cells were first isolated in 1998 at the University of Wisconsin (Thomson et 
al., 1998).  Scientists at the Wisconsin Regional Primate Centre in Madison in November of 
1998 isolated human ES cells from excess embryos they had obtained from various in vitro 
fertilization clinics (Weiss, 2005).  One year later, scientists at John Hopkins University isolated 
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their human ES cells from primordial germ cells of aborted foetuses (Shamblott et al., 1999).  
These scientific teams expected their discoveries would bring applause and admiration, but 
instead the discovery was overwhelmed with controversy and debate, as it re-ignited old debates 
about the use of embryos in research that had been raging since the first human IVF procedures 
were performed in the late 1960’s and early 1970’s.  As will be discussed in Chapter-3, some 
religious groups argue the destruction of the embryo is murder, so oppose working with 
embryos.  Some went to the extent of terming this new ES cell isolation process as 
“cannibalism” (Weiss, 2005).  However, not all religions are against working with embryos, and 
as more diseases are being researched for treatment, more people are starting to rethink their 
earlier ideas about stem cells.  
The pluripotent ability of ES cells to develop into almost any type of cell in the body is 
the primary reason these cells are of great interest to scientists. Scientists hope to be able to learn 
how to differentiate ES cells in vitro into all cell types, including nerve cells, heart muscle, organ 
tissue, and many other types (Figure-3) in the hope of curing a variety of diseases and increasing 
life expectancy.  Some of the advances in this direction will be discussed in Chapter-2. 
 
 
 
 
 
 
Figure-3:  ES Cell Differentiation.  
Diagram shows the various types of 
tissues scientists hope to be able to 
differentiate ES cells into in vitro. 
(Mohit, 2010) 
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The problem with ES cells is they destroy an embryo to isolate them.  In the US, embryos 
for this use are obtained from reproductive IVF clinics.  It is currently not legal in the US to 
create embryos solely for research purposes, so they must be obtained from excess IVF embryos 
with donor consent (In Vitro Fertilization, 2006). After the IVF zygote is created, it progresses 
through several cell divisions until it becomes a blastocyst which takes about five days.  The 
blastocyst consists of an inner cell mass (containing ES cells) and the outer cell mass. Extracting 
the inner cell mass from the embryo destroys it. Usually during reproductive IVF procedures 
excess embryos are created.  If those embryos are not used by the parents, with their signed 
consent the embryos can be donated for research purposes (Weiss, 2005).  
The isolated inner cell mass cells are plated on a feeder layer to provide a scaffold for 
growth.  Initially, the feeder layer was irradiated mouse fibroblast cells, but to avoid possibly 
contaminating the ES cell lines with animal products from the animal feeder layer the protocols 
were adapted to use human cell feeder layers.  Once an ES cell line has been established, 
research can commence. 
 
Figure-4:  Isolation of ES Cells from Blastocyst Embryos.  Diagram 
illustrates the process of isolating the inner cell mass (blue) from 5-day old 
blastocysts, and plating them on a feeder layer (yellow) to provide a scaffold 
for growth.  (Winslow and  Duckwall, 2001)  
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Although human ES cells have been differentiated in vitro into cells secreting dopamine 
(for treating Parkinson’s disease), insulin (for treating type-I diabetes), or myosin (for creating 
muscle cells), scientists are still researching ways to differentiate them into all known tissue 
types.   
 
iPS Cells 
Because many people still view sacrificing an embryo to be murder, scientists are 
constantly seeking ways to create pluripotent stem cells without using embryos.  One of the 
hottest topics in all of stem cell research in the past few years is the induction of pluripotent stem 
cells directly from skin cells using genetic reprogramming.  These cells are termed induced 
pluripotent stem (iPS) cells.  iPS cells were first derived from skin cells from mice (Takahashi 
and Yamanaka, 2006) and a year later were derived from skin cells in humans (Takahashi et al., 
2007).  Initially the reprogramming was performed by using a virus to deliver four genes 
encoding transcription factors for Oct3, Sox2, c-Myc, and Klf4 into the skin cells.  The 
transcription factors bound DNA in the cells to induce a reprogramming to a pluripotent-like 
state.  In some cases the implanted iPS cells causes tumor formation, so later protocols omitted 
the c-Myc oncogene component, and also eliminated the virus method of delivery.   This process 
does not destroy embryos, so these cells are potential replacements for ES cells, so long as they 
are truly pluripotent.  However, recent experiments indicate iPS cells may contain DNA 
mutations (Lister et al., 2011), so further research will be required to determine whether iPS cells 
can be used for therapies. 
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CHAPTER-2: STEM CELLS APPLICATIONS 
Divya Panickar 
 
For years, doctors and researchers struggled to cure many diseases, but little did they 
realize that every human is born with, and retains, a special type of cell that might help treat 
many types of disorders.  Because of their ability to divide and to differentiate into a variety of 
tissues, stem cells represent the medicine of the 21st century.  As discussed in Chapter-1, these 
cells (depending on their type) have the ability to form heart tissue, neurons, skin cells, and 
various other tissues (Figure-1). Adult stem cells are found in our own organs and tissues such 
as fat, bone marrow, umbilical cord blood, placenta, brain, and olfactory tissue (Hughes, 2005).  
The purpose of this chapter is to go beyond a discussion of stem cell types to document the 
various ways that stem cells are being used.  Such “benefits to society” are important to 
document prior to our discussion of stem cell ethics.  
 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: The Potential Uses of Stem Cells.  The figure shows the 
various uses of stem cells for treating diseases affecting different parts of 
the body.  (New Stem Cell Research, 2010) 
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The potential stem cell applications discussed in this chapter include blood cancers, 
spinal cord injuries, diabetes, heart attacks, and lung cancer.  In each case, an attempt is made to 
update the reader up on the use of either embryonic stem (ES) cells stem cells or adult stem cells 
(ASCs) to treat either animal models of a disease or human patients.  Adult stem cells are less 
controversial since they can be isolated from adult tissue samples or from umbilical cord blood, 
and do not require embryos, but these cells are hard to obtain and hard to grow.  So it is 
important to note whether ACSs can effectively treat a particular disorder, or must ES cells be 
used.  However, ES cell lines are harder to obtain funding for, and may produce tumors upon 
implant.  Data will be provided for induced pluripotent stem (iPS) cells when available, since 
these cells do not destroy an embryo to obtain them, yet they appear to be pluripotent.  In 
addition to academic labs, many drug companies are also showing strong interest in stem cell 
technologies. Roche, for example, made a deal with Harvard University and Massachusetts 
General Hospital to focus on stem cell-based drug screening. Other companies that have made 
similar deals include Pfizer, GE healthcare, Novocell, GlaxoSmithKline, AstraZeneca and 
Cellartis (Baker, 2010). 
 
 
Hematopoietic Stem Cells (HSCs) Applications 
 
Hematopoietic stem cells (HSCs) are multi-potent stem cells that can give rise to all types 
of blood cells using myeloid and lymphoid lineages (Figure-2).  The main uses of HSCs are 
bone marrow transplants (BMT).  In a bone marrow transplant, the patient’s diseased bone 
marrow is destroyed by chemotherapy or irradiation, and healthy marrow is infused into the 
patient’s blood stream. HSCs are used to treat leukemia, lymphoma, aplastic anemia, 
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thalassemia, sickle cell anemia, and autoimmune diseases.  Bone marrow transplants have been 
performed for decades now, saving thousands of lives, making HSCs the best characterized of all 
types of stem cells (reviewed by Donnall, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-2: Diagram of Hematopoiesis.  Diagram shows the formation 
of all blood cell types from a hematopoietic stem cell (upper center, cell 
labeled hemocytoblast).  (Histology, 2000) 
 
Leukemic cells are known to be highly sensitive to irradiation. Chemotherapy or 
irradiation kills the affected cells and also normal cells of the bone marrow.  So transplantation 
of a new healthy marrow is required.  Early attempts to treat leukemia in mice by BMT, in 1956 
by Barnes, included the treatment of leukemic mice by supra-lethal irradiation, followed by the 
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infusion of normal mouse marrow. The allogeneic (histo-compatible, although not identical) 
marrow cells became successfully engrafted.   
Traditionally HSCs are obtained under local anesthesia from bone marrow using a 
syringe.  However, more recently scientists obtain HSCs from peripheral blood from individuals 
treated with hematopoietic growth factors (GM-CSF or G-CSF) to stimulate the release of HSCs 
into the peripheral blood system.  HSCs can also be obtained from cord blood.   
BMTs have also been used to treat autoimmune diseases. Total body irradiation followed by an 
allogeneic stem cell engraftment is the most curative approach; however it includes 
complications from T-cells similar to those stated for the treatment of leukemia, immune 
rejection.  Some scientists have tried storing a patient’s own peripheral blood HSC s for future 
morrow rescue, then giving a higher dose of immunosuppressive agents to see whether there is 
an improvement over conventional chemo doses.  Others who prefer a more conservative 
approach give myeloablative and lymphoablative chemotherapies together followed by purified 
(lymphocyte-free) HSCs.  Third, and most likely to be curative, is myeloablative and 
lymphoablative therapy followed by HSCs from an HLA-identical matched family member with 
subsequent short methotrexate and cyclosporine treatment to control GVHD (Donnall, 2000). 
Another successful application of HSCs is in the transplantation of umbilical-cord blood in 
babies with infantile Krabbe’s disease, a disease with no cure.  In some experiments, 100% 
survival was obtained in the transplantation of umbilical-cord blood from unrelated donors in 
asymptomatic newborns with infantile Krabbe’s disease, while only 43% survived in 
transplantation in babies after symptoms had developed (Escolar et al., 2005; NIND, 2011). 
Surprisingly, HSCs also find their application in muscle regeneration. This is an application 
outside the normal ability of HSCs to differentiate, and shows their possible plasticity.  
 23 
Genetically marked bone marrow transplantation performed in immune-deficient mice has 
shown that the HSCs migrate to degenerated muscle and differentiate to regenerate the damaged 
muscle fibers. These marrow-differentiated myogenic progenitors could be used to target 
affected/degenerated muscles, thus offering an alternative successful treatment of muscular 
dystrophies (Ferrari et al., 1998).  
Another remarkable possibility in the application of HSCs is their use in providing 
neurons. It was shown that in a strain of mice incapable of developing cells of myeloid and 
lymphoid lineages, transplanted adult bone marrow cells migrated to the brain and differentiated 
into cells that expressed neuron-specific antigens.  Thus, an alternative source of neurons might 
be obtained from bone marrow cells differentiated into a neuronal lineage. This would help treat 
patients with neurodegenerative diseases or central nervous system injury (Mezey et al., 2000). 
 
 
Spinal Cord Injuries 
 
Spinal cord injuries can be caused by direct damage to the cord itself or by damage to 
surrounding blood vessels, bones, or tissues which destroy the spinal cord support system. These 
injuries cause destruction or damage of various cells including neurons. In acute CNS injuries, 
the axons carrying signals from the brain to the body, and vice versa, do not function properly, 
which can lead to total paralysis or in other cases a lack of sensation in some parts of the body.  
          Astrocytes are star shaped glial cells found in the brain and spinal cord that perform a 
variety of functions in the CNS including repair. Transplantation of rat astrocytes derived from 
embryonic glial-restricted precursors has shown healthy axon growth and restoration of 
locomotor function following acute transection injuries of the adult rat spinal cord. The ability of 
such astrocytes to fill the injury site, suppress gliosis, realign host tissues, and delay expression 
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of axon-growth-inhibitory proteoglycans, suggests that these cells are unusually effective in 
providing an environment that supports axon growth for acute CNS injuries (Davies, 2006). 
In adult rats with motoneuron injuries, embryonic stem (ES) cell-generated spinal motoneurons 
were transplanted into spinal cords.  The cells extended long axons, formed neuromuscular 
junctions, and induced muscle contraction when co-cultured with myoblasts. It was found that 
about 3000 of these motor-neurons (25% input) survived for over a month in the spinal cord of 
each animal. The axonal growth was inhibited by myelin, however this inhibition was overcome 
by administration of dibutyryl cAMP (dbcAMP) in vivo and in vitro. These studies are important 
since they show the potential of creating neural circuits in vivo after deriving the cells in vitro 
(Harper et al., 2004). 
After these initial rat studies, experiments with human ES cell-derived neurons were 
performed, although the human cells were transplanted into rats not humans.  Human ES cells 
have been shown to be capable of forming several types of CNS tissue, including neurons, oligo-
dendrites, and astrocytes (Figure-3).  Since spinal cord trauma causes demyelination which 
contributes to loss of functioning of the axons, a potential therapeutic strategy involves re-
myelination of the axons. This requires myelin-forming cells to repair the damaged neurons. 
Transplantation of human ES cell-derived oligo-dendrite progenitor cells (OPCs) into the spinal 
cord of adult rat suffering spinal cord injuries has been shown to enhance re-myelination and 
promote improvement of motor function.  Rats that were injected with OPCs 7 days after injury 
showed enhanced re-myelination and substantially improved locomotor ability, while those 
injected with OPCs 10 months after injury exhibited no enhanced re-myelination or locomotor 
recovery. These studies show that in both cases the transplanted cells survived, redistributed over 
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short distances, and differentiated into oligodendrites, but the transplants are helpful in treating 
spinal cord injuries only when provided at early stages (Kierstead et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3:  Cell Types Derived from ES Cells to Help Repair Spinal Cord Injuries.  
Human ES cells have been shown to be capable of forming neurons, oligo-dendrites, and 
astrocytes in vitro.  (Hall, 2005) 
 
 
The world’s first human clinical trial of cells derived from human ES cells has been 
approved and has begun a little more than 10 years after the first human ES cells were isolated at 
the University of Wisconsin (Thompson et al., 1998). The Food and Drug Administration only 
recently approved the human stem cell clinical trial for treatment of  spinal cord injuries to Geron 
Pharmaceuticals. The trial is in its first phase with no data yet available. Years of testing will be 
required before the treatment will be available to more patients.  Some scientists have expressed 
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concern with the safety of these trials, arguing that the animal tests performed previously showed 
success only in moderately injured animals. Others fear that when ES cells are put into the body, 
chances are high that they will form unwanted tumors.  Even if not malignant, any tumor in the 
spinal cord could further damage the nerves.  Dr. Okarma of Geron however said that they had 
done numerous studies showing that these differentiated cells did not contain residual ES cells, 
and did not form tumors in animals even after one year.  Geron submitted over 22,000 pages of 
data to the FDA, perhaps the largest application ever to begin a clinical trial, before gaining 
permission (New York Times, 2009).  
 
Treatment of Diabetes 
Diabetes mellitus, simply known as diabetes, is a group of metabolic diseases in which a 
person has high blood sugar, either because the body does not produce enough insulin or the 
body fails to respond to the insulin produced.  Diabetes currently affects about 7% of the world’s 
population, nearly 250 million people worldwide (Goldthwaite, 2006).  All forms of diabetes 
have been treatable (but not curable) since insulin became available.  Type-I diabetes is treated 
with insulin injections, while type 2 diabetes, the more common type, is controlled with diet, 
exercise, and other medications.  
Researchers have been considering cell replacement therapy as a potential strategy to 
treat type-I diabetes, since patients with this form of the disease have lost all pancreatic β-cells.  
These cells normally provide insulin for controlling blood sugar levels (Figure-4).  Cell 
replacement therapy might also help treat type 2 diabetes since replenishing β-cells would help 
prevent their insulin deficiency.  However, a major challenge in cell replacement therapy is an 
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insufficient supply of β-cells from human organ donors. Thus, researchers have been exploring 
stem cells as a possible therapeutic option.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Diagram of the Human Pancreas.  The pancreas consists of 
β-cells that produce and release insulin into adjacent blood vessels.  
Insulin facilitates the uptake of glucose into cells of tissues such as 
muscles, and is lacking in patients with Type-I diabetes.  (Terese et al., 
2001)  
 
In cell therapy for type-I diabetes, stem cells capable of differentiating into β-cells in 
response to molecular signals could be introduced into the body, where they can migrate and 
differentiate into insulin producing β-cells.  Alternatively, stem cells could also be allowed to 
differentiate into insulin producing β-cells in vitro, then could be transplanted into the patient.  
ES cells have already been shown to be capable of a differentiation process similar to in vivo 
pancreatic organogenesis. In this process, the human ES cells are directed through embryonic 
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stages resembling endoderm, gut-tube endoderm, pancreatic endoderm and endocrine precursor, 
which eventually form endocrine cells capable of synthesizing the pancreatic hormones insulin, 
glucagon, somatostatin, pancreatic polypeptide, and ghrelin. These ES cell-derived insulin-
expressing cells release C-peptide (a peptide indicating the synthesis and maturation of true 
insulin) in response to multiple secretory stimuli. The cells also have an insulin content 
approaching that of adult islets (D’Amour, 2006). 
Another treatment might include bone marrow derived stem cells to regenerate a 
damaged pancreas. Experiments were performed by transplanting adult bone marrow-derived 
stem cells (expressing the cell surface marker c-kit) into mice with pancreatic damage.  The 
majority of transplanted cells localized to islet and ductal structures, and their presence caused 
proliferation of recipient pancreatic cells resulting in the production of insulin.  This experiment 
showed that the transplantation of adult bone marrow-derived cells expressing c-kit reduced 
hyperglycemia in mice with streptozotocin-induced pancreatic damage (Hess et al., 2003). 
With respect to the treatment of diabetes with induced pluripotent stem (iPS) cells, a specific 
combination of three transcription factors [Ngn3 (also known as Nuerog3), Pdx1 and Mafa] was 
found to reprogram differentiated mouse pancreatic exocrine cells into cells closely resembling 
β-cells (Zhou et al., 2008). This was a controlled process of adult reprogramming, and the 
induced β-cells were indistinguishable from endogenous islet cells in size, shape, and 
ultrastructure.  They could secrete insulin and ameliorate hyperglycemia. This type of controlled 
conversion is essential to avoid cancer formation (Zhou et al., 2008).  
In another experiment, a new model of β-cell regeneration was tested combining 
pancreatic duct ligation (PDL) (to stimulate in vivo cell formation) with the elimination of pre-
existing β-cells with alloxan (Chung et al., 2010).  A large number of β-cells were generated in 
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only 2 weeks.  The neogenic β-cells appeared to arise primarily from alpha-cells by direct 
conversion, with or without intervening cell division. Within a week following the approach, an 
intermediate cell type between β-cells and alpha-cells was observed, and by the end of 2 weeks 
most of the intermediate cells were observed as mature β-cells, which lacked glucagon (an alpha 
cell marker) and expressed Mafa (a β-cell marker).  Since the conversion is an efficient and rapid 
process, its application in treating diabetes holds great potential (Chung et al., 2010).  
 
Treatment of Damaged Heart Muscles 
When heart muscles are damaged due to a heart attack, bone marrow stem cells travel to 
the site of damage to help repair and restore the cells.  However, for some reason, the molecular 
signals that recruit these stem cells to the heart are present only for a very short period of time, 
leaving most of the repair work undone.  The partially repaired tissue makes the heart work 
harder and less efficiently, which can eventually lead to a second heart attack (Stem Cell 
Therapy, 2009).  A cell therapy trial conducted by researchers in Germany and Switzerland 
involved infusing heart attack survivors with a solution including progenitor cells from their own 
bone marrow and other patients with a placebo solution.  The study results showed that after two 
years, no patients that received the progenitor cells had suffered a second heart attack, while 
seven patients that received the placebo solution did.  The progenitor cell-treated patients were 
also less likely to die, need new revascularizations, or be re-hospitalized for heat failure (Science 
Daily, 2009). 
Ischemic cardiomyopathy is a term used to describe patients who have reduced heart 
pumping capacity due to coronary heart disease.  This causes a reduced supply of blood and 
oxygen to the heart muscles. As the current therapies to treat ischemic cardiomyopathy have 
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their limitations, researchers have aimed at regenerating and repairing ischemically damaged 
myocardium though stem-cell therapy, to restore the thickness of the affected myocardium and 
reduce infarction so that the heart could pump more efficiently. Various clinical trials using 
skeletal myoblasts and autologous bone-marrow stem cells shows results such as 60% wall 
thickening across the ischemic myocardium, improved systolic function, improved exercise 
capacity, improved cardiac function, significant reduction in infarct size, and an increase in 
stroke volume (Rosenstrauch et al., 2005).  The cell therapy approach has initially proven so 
successful that a variety of clinical trials are ongoing (Figure-5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Cell Therapy Clinical Trials for Heart Disease.  
Shown are the trials undertaken by various sponsors, the stem cell 
types used, and the current phase of the clinical trial (Baker, 2009). 
 
 
A striking new experiment undertaken by researchers at the John Hopkins Institute for 
Cell Engineering demonstrated a highly efficient system for the differentiation of human ES cells 
and human iPS cells to a cardiac lineage to produce functional cardio-myocytes.  The system 
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employed the forced aggregation of contracting human embryoid bodies (hEB) (to provide ES 
cells).  The produced cells contained a high percentage of cardiac troponin I(+) cells that looked 
morphologically like cardiomyocytes, and uniform electrophysical profiles responsive to cardio-
active drugs.  The system appears to be cost-effective, and produces unlimited functional 
myocytes that can be used for cardiac disease modeling (Burridge et al., 2011). 
Human umbilical cord stem cells have also been used to treat animal models of heart 
attacks (Figure-6).  In an experiment conducted in mice following myocardial infarction, human 
umbilical cord blood (hUCB) cells were injected intravenously.  They migrated to the damaged 
tissue, not normal myocardium, and engrafted, participated in neo-angiogenesis, and influenced 
tissue remodeling (Ma et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-6: Use of Adult Stem Cells to Treat Heart Attack Damage.  
When the adult stem cells of a mouse were injected into damaged 
myocardium, the stem cells regenerate and repair the damaged heart 
muscle. When human adult bone marrow stem cells were injected into a 
rat tail, the stem cells induced new blood vessel formation.  (Terese et 
al., 2001) 
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Lung Cancer 
 
An uncontrolled cell division in the lungs is lung cancer.  The two types of lung cancer 
are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).  SCLC is the more 
common type, caused mainly by smoking. The current therapies used for SCLC are surgery, 
radiotherapy, or chemotherapy etc.  The main issue with chemotherapy/radiation therapy is much 
normal tissue is destroyed along with the tumor, which causes patients to experience fatigue and 
other side effects.   So researchers have explored the use of stem cells to treat lung cancer 
(Figure-7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-7: Tumor Formation in the Lung.  Schematic representation of 
the airways and the cell types present in each region of the lung. The red 
arrows indicate cells types having stem cell potential, also possibly 
linked to tumor formation. The circles on the right side diagram of the 
bronchi indicate the locations of different lung cancer forms. 
Abbreviations are:  AC-Adenocarcinoma; SCLC-Small Cell Lung 
Cancer; SCC-Squamous Cell Carcinoma.  (Eramo et al., 2010) 
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Generally, patients receiving intensive radiotherapy followed by radiotherapy seldom 
survive.  However, the use of stem cell-enriched whole blood during intensive chemotherapy has 
now been shown to enhance chest radiotherapy in SCLC (Calderoni et al., 2002).  In a short 10 
weeks treatment, 18 patients were treated with intensive chemotherapy with the support of 
unprocessed stem cell-enriched whole blood and chest radiotherapy. The results were compared 
with a previous treatment including six cycles of standard chemotherapy followed by chest 
radiation.  It was clear that the short and intensive radiotherapy regimen in the presence of cell 
therapy was well tolerated and showed promising survival results (Calderoni et al., 2002). 
Better than treating lung cancer would be to prevent it. Scientists have identified lung 
stem cells in the lung airways that are believed to initiate cancer formation (Pine et al., 2008). 
These stem cells have pro-tumorigenic characteristics, including a high proliferative capacity, 
multi-potent differentiation, drug resistance, and long lifespan.  If scientists can re-program these 
stem cells to not form tumors, perhaps lung cancer could be prevented.  Stem cell signaling and 
differentiation pathways are maintained for distinct cancer types, and a destabilization of this 
machinery might help control tumor formation. However, this application is just a theory (Pine et 
al., 2008). 
Researchers have also used ES cells to treat lung cancer in mice (Science Daily, 2006).  
Vaccination of mice with ES cells prevented lung cancer when cancer cells were transplanted 
into them following the stem cell vaccination. However, these studies are in the early stages, and 
human clinical trials are not underway yet (Science Daily, 2006). 
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Stem Cells and Food Applications 
 
Stem cells might also be used to create animal tissues that when cultured with the right 
amounts of proteins can mimic the taste and texture of meat.  This could be a revolutionary 
achievement since artificial meat could offer a green alternative to raising livestock, help 
alleviate world hunger, and help prevent animal slaughter (Cheng, 2010). According to the 
analysis by scientists at Oxford University and Amsterdam University, lab-grown meat would 
reduce greenhouse gases by up to 96% in comparison to raising animals, reduce energy 
requirements by 7%-45%, and use only 1% of land and 4% of the water associated with 
conventional meat raising (Harvey, 2011). 
Several groups in the U.S., Scandinavia, and Japan have been researching ways to create 
meat in the laboratory, but the Dutch project may be the most advanced as they have been 
working on this since 2006, but they have not yet achieved the right texture or taste.  So far, they 
have succeeded in creating 1cm long strips of pork (Figure-8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-8: Photograph of Artificial Meat.  Shown are strips of pork 
1cm long created from pig stem cells.  (Cheng, 2010) 
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To create these strips, a pig’s muscle-derived stem cells were isolated and placed in a 
nutrient culture that helped the cells replicate. It took about 30 days to grow a centimeter long 
pork strip.  The texture of the strips however was soft like scallop, and moist due to lesser protein 
compared to conventional meat.   
On a similar note, fish stem cells could be used to produce healthy omega-3 fatty acids, 
which could be mixed with the lab-produced pork to create a healthier product, perhaps for use 
in sausages or hamburgers. The main problem is reproducing the protein content in regular meat: 
In livestock meat, protein makes up about 99% of the product; the lab meat is only about 80% 
protein (Cheng, 2010).  Creating edible artificial meat is a win-win situation for all, so hopefully 
this will be successful in the near future. 
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CHAPTER-3: STEM CELL ETHICS 
Nirali Parekh 
 
 
Although stem cells carry with them a great power to heal, some types also carry a great 
deal of ethical roadblocks.  Considering the sources of embryonic stem cells, many people feel 
that certain types of work should be deemed unethical, immoral, or even murder. Not since the 
Roe v Wade Supreme Court decision of 1972 legalizing some types of abortion has there been so 
hotly debated a topic (Roe v Wade, 1972).  The purpose of this chapter is to frame the stem cell 
debate, and to discuss the various religious stances on the topic, as an example of the effects of 
technology on society. 
 
Framing the Stem Cell Debate 
From Chapter-1, we know there are several types of stem cells. Adult stem cells (ASCs) 
are isolated from an adult tissue and do not destroy embryos to obtain them.  Examples include 
hematopoietic stem cells, neuronal stem cells, stromal stem cells, and epithelial stem cells, etc.).  
Embryonic stem (ES) cells are usually isolated from a blastocyst, an embryo about 5 days old, 
the size of the period at the end of this sentence.  The blastocyst has the potential to become an 
adult if implanted into the uterus, so some call its destruction murder. 
In September 2005, a Gallup poll of 1,002 adults nationwide (Table-I) asked their 
opinions about the origins of human life, how much this opinion affected their life, and whether 
their religious and scientific beliefs conflicted (CNN, 2005).  It shows that 84% of people believe 
that God had at least some role in the evolution of humans, and 76% of people have thought 
about the origins of man at least a moderate amount (CNN, 2005). Though this only illustrates 
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the idealism of a monotheistic, or the belief in a singular entity in religions like Christianity or 
Judaism, this poll shows that the United States could be even more divided on whether humans 
should interfere with the “natural process of life,” especially when 66% of the people polled 
believe that their theological beliefs about creation mean a great deal or moderate amount to 
them (CNN, 2005). Some religions believe that stem cell usage is murder, and that scientists are 
playing God (Ayon, 2002). What makes this question even more complicated is that stem cells 
are not all alike, and the religious views differ on each type.  As the poll shows, 35% of people 
find that their religious and scientific beliefs conflict with each other (CNN, 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table-I: CNN/USA Today/Gallup Poll. Sept. 8-11, 2005. 
N=1,005 adults nationwide. MoE ± 3 (CNN, 2005) 
 
 
 
“Which	  of	  the	  following	  statements	  comes	  closest	  to	  your	  views	  on	  the	  origin	  and	  development	  of	  human	  
beings?	  Human	  beings	  have	  evolved	  over	  millions	  of	  years	  from	  other	  forms	  of	  life	  and	  God	  guides	  this	  process.	  
Human	  beings	  have	  evolved	  over	  millions	  of	  years	  from	  other	  forms	  of	  life,	  but	  God	  had	  no	  part	  in	  this	  process.	  
OR.	  God	  created	  human	  beings	  in	  their	  present	  form	  exactly	  the	  way	  Bible	  describes	  it.”	  Options	  rotated	  
	  
	   Evolved,	  
God	  Guided	  
%	  
Evolved,	  God	  
Had	  No	  Part	  
%	  
Exactly	  As	  Bible	  
Describes	  
%	  
Other	  (vol.)	  
%	  
Unsure	  
%	  
9/8-­‐11/05	   31	   12	   53	   1	   3	  
	  
“How	  much	  have	  you,	  personally,	  thought	  about	  these	  different	  explanations	  for	  how	  human	  beings	  came	  to	  
exist	  on	  earth:	  a	  great	  deal,	  a	  moderate	  amount,	  not	  much,	  not	  at	  all?”	  
	   A	  Great	  Deal	  
%	  
A	  Moderate	  
Amount	  
%	  
Not	  Much	  
%	  
Not	  At	  All	  
%	  
Unsure	  
%	  
9/8-­‐11/05	   41	   35	   17	   6	   1	  
	  
“How	  much	  does	  it	  matter	  to	  you	  which	  of	  those	  theories	  is	  correct:	  a	  great	  deal,	  a	  moderate	  amount,	  not	  
much,	  not	  at	  all?”	  
	   A	  Great	  Deal	  
%	  
A	  Moderate	  
Amount	  
%	  
Not	  Much	  
%	  
Not	  At	  All	  
%	  
Unsure	  
%	  
9/8-­‐11/05	   40	   26	   19	   14	   1	  
	  
“Which	  comes	  closer	  to	  your	  view	  about	  the	  relationship	  between	  science	  and	  religion?	  They	  generally	  agree	  
with	  each	  other.	  They	  generally	  conflict	  with	  each	  other.	  OR.	  They	  are	  not	  related	  to	  each	  other	  in	  any	  
meaningful	  way.”	  
	   Generally	  
Agree%	  
Generally	  
Conflict	  
%	  
Not	  Related	  
%	  
Unsure	  
%	  
9/8-­‐11/05	   24	   35	   36	   5	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Almost all religions accept adult stem cells, but some believe that the use of embryonic 
stem cells is sacrilegious, depending on whether they view life as beginning at conception (thus 
working with a 5-day embryo is murder) or life begins at day-40 or birth (thus working with a 5-
day embryo is not murder). As it can be imagined, religious controversy about stem cells is a 
major obstacle for the continuation of its research. For this reason stem cell ethics is a 
worthwhile discussion. 
 
 
 
Number of Embryos Destroyed versus Lives Saved 
Some individuals may not be aware of the power that is at our disposal with stem cells. 
One human embryo can produce about forty primary ES cells (Weiss, 2005), and these primary 
cells can sometimes be grown in ES cell lines to create millions of cells.  In addition, in vitro 
fertilization (IVF) clinics usually create excess embryos not used by the parents for reproduction, 
so there is a debate about what to do with the approximate 400,000 frozen embryos in storage 
inside IVF clinics (Freking, 2005).  Should the excess embryos (with donor consent) be used to 
try to save lives?  Those forty ES cells could be cultured in a medium and under the right 
conditions can produce millions of healthy cells, and can replicate infinitely. The number of 
people that can be saved from these cells would be endless (Scientists Match ….2005).  So, 
every embryo has the potential to save many lives through ES cell lines. Why should we throw 
away many existing lives for the sake of one potential life the size of a dot.   
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Religious Stances on Stem Cells 
Hinduism and Buddhism Ethics 
Hinduism is a dominant Asian religion that varies significantly in traditions and beliefs. 
Closely related to Hinduism is Buddhism.  A fundamental tenet of Hinduism and Buddhism is 
the importance of practicing compassion toward others. Medical research, with its aim to help 
others is, therefore, viewed favourably in these religions, so adult stem cell research is widely 
accepted (Knowles, 2011).  The traditional Hindu belief is that life begins at conception, which is 
the point when a person is reborn from their previous life, or reincarnated.  Some believe that 
‘ensoulment’ or the beginning of personhood takes place between the 3 and 5 month of gestation.  
However, Swami Tyagananda, a Hindu chaplain at the MIT Religious Activities Center, argues 
that ES cell research and therapy may be justifiable as it is considered an “extraordinary, 
unavoidable circumstance,” and an act done “for the greater good” (Reichhardt, 2004). While 
abortion and any other kind of killing of the fetus at any stage are considered murder, abortion is 
still practiced in some rural parts of India in the Hindu culture because of the cultural preference 
for boys. So as is typical of many religions, the theoretical may differ from the actual practice. 
An additional central tenet of the Hindu religion is the mandate to avoid harming other 
living things. Life in all its forms is viewed as sacred, and this mandate to avoid harm mediates 
against ES cell research since the embryo is seen as a living being. While views on the moral 
status of the human embryo differ, in traditional Hindu belief, conception is the beginning of a 
soul’s rebirth from a previous life.  Some Hindu traditions place the beginning of personhood 
between three and five months of gestation, while few believe that the soul’s rebirth can occur as 
late as the seventh month. Most Buddhists have adopted the classical Hindu teaching that 
personhood begins at conception (Knowles, 2011).  
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Buddhism does not believe in a “divine creator, whose plan might be distorted by human 
tinkering with nature” (Frazzetto, 2004). They follow the teachings of the Buddha Sakyamuni.  
In Buddhism, ethics is more a matter of personal choice; principles like the one of ‘non-harming’ 
should be followed as guidelines” (Schlieter, 2004).  Therefore, there are many interpretations of 
when life begins and what the consequences are to your karma. Karma is believed to be a sum of 
all of your actions in your current, past, and future lives. Therefore, how you act in one life will 
affect your reincarnation, or rebirth. 
Damien Keown, a well-known expert on Buddhist biomedical issues, explains that 
“Buddhism teaches that life may come into being in a variety of ways, of which sexual 
reproduction is but one, so sexual reproduction has no divinely sanctioned priority over other 
modes of procreation” (Frazzetto, 2004).  Buddhist teachings about embryology assume “that the 
transmigration of consciousness is sudden rather than gradual” (Hughes and Keown, 1995).  
However, an article by James Hughes, from the MacLean Center for Clinical Medical Ethics and 
by Damien Keown, of the University of London, explains that there are a variety of views of 
when Buddhists believe ensoulment occurs: 
“Based on the findings of modern neuro-embryology, Buddhists today might 
maintain that the fetus does not fully embody all five skandhas and the illusion of 
personhood until after birth; this is the argument developed by most Western 
ethicists to defend abortion. If the fetus is not yet a fully embodied person, then the 
karmic consequences of abortion would be even less than the killing of animals, 
which Buddhism teaches do have moral status. This neurological interpretation of the 
skandhas may be more consistent with Western Buddhism, which often sees the 
doctrine of rebirth as peripheral or interprets rebirth metaphorically rather than 
literally” (Hughes and Keown, 1995). 
 
Consequently, the actual definition of when life begins is not an exact time. Therefore there are 
two main interpretations about this in Buddhist teachings. A small segment of Buddhists believes 
that incarnation or conception “does not occur until as late as the seventh month.” Though there 
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is another larger segment that believes the “transmigration of consciousness occurs at 
conception, and therefore that all abortion incurs the karmic burden of killing” (Hughes and 
Keown, 1995). Though abortion occurs later in the development of the fetus (well after a day5 
blastocyst), it could be inferred that this segment of the Buddhist would believe that stem cell 
research would have the name moral effects as abortion because the status of the fetus is the 
same at any point of its development. Though this might seem a reasonable rationale, it is still 
not so clear what Buddhism’s view on stem cells is. Buddhism “encourages placing a strong 
value on respecting every living being, which includes fertilized embryos used for research 
activities” (Frazzetto, 2004). 
 
Christianity Ethics 
Christianity is the world’s largest religion, and the beliefs vary for different 
denominations.  Some Christians approve of ES cell research under certain conditions, while 
others believe that it is unethical under any circumstances. The majority of Christians believe 
that life begins at conception and is sacred from that moment on. 
Catholic officials are strictly opposed to the destruction of embryos under any conditions.  
ES cell research is “immoral, illegal, and unnecessary,” as said by the U.S. Roman Catholic 
Bishops (Religious Views…2001).  Catholicism is the only major religion opposed to in vitro 
fertilization (IVF) methods which are the main sources for ES cells. The IVF clinics often 
destroy excess embryos not used for reproduction, and these embryos could be used as a source 
of ES cells.  However, the Catholic Church believes that this popular method for allowing 
infertile couples to have children “breaks the God-given connection between sex and 
procreation” (Reichhardt, 2004).  When speaking about embryonic stem cell research, 
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Archbishop Francis E. George stated that "history has shown that it is always the dispossessed, 
those whose lives are easily overlooked, who are subjected to the worst abuses of scientific 
research,'' and that the "so-called 'spare' human embryos are particularly vulnerable to this kind 
of moral blindness because so many people seem to have difficulty identifying with their 
humanity'' (US Bishops, 2006).  
Even those Christians that do not believe the embryo is fully human argue that they are 
still “deserving of respect”. They believe that life begins at fertilization, biologically speaking 
this is believed to be the beginning of a new human life (Shannon, 2006). Professor Thomas 
Shannon goes on to explain that “together with this affirmation is the correlative presumption 
that this is the time of the infusion of the soul. Although there is no official Catholic doctrine on 
this position, the attitude of the Church is that moral priority should be given to this position” 
(Shannon, 2006). The Catholic church believes that no matter how insignificant in size it may be, 
it is still life says Bishop Donald Wuerl, "while (a stem cell) is a tiny speck, it nonetheless 
contains the elements out of which comes the fully developed human person'' (US Bishops, 
2006). Pope John Paul’s II address to the diplomatic corps on January 10, 2005 seems to 
exemplify the Catholic position: 
“Conflicting views have been put forward regarding abortion, assisted procreation, 
the use of human embryonic stem cells for scientific research, and cloning. The 
Church's position, supported by reason and science, is clear: the human embryo is a 
subject identical to the human being which will be born at the term of its 
development. Consequently whatever violates the integrity and the dignity of the 
embryo is ethically inadmissible. Similarly, any form of scientific research which 
treats the embryo merely as a laboratory specimen is unworthy of man.” (Pope, 
2005) 
 
The Pope goes on to explain that “scientific research in the field of genetics needs to be 
encouraged and promoted, but, like every other human activity, it can never be exempt from 
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moral imperatives; research using adult stem cells, moreover, offers the promise of considerable 
success” (Pope, 2005).   
There are a few within the Christian church that support ES cell research, arguing that the 
embryo represents the potential for life but does not yet have the moral status of a born child. 
This stance argues embryos should not be bought or sold (Farley, 2000), but can be used to save 
lives. Doctor Ronald Cole-Turner of the Pittsburgh Theological Seminary and a member of the 
Protestant denomination, the United Church of Christ, explains that the majority of the members 
believe “that embryos have an important but less status” (Cole-Turner, 2000).  The General 
Synod, the church-wide counselling body which is the voice of the church on particular issues, 
released a statement that the “human pre-embryo” should be treated with the utmost respect, but 
that it has only the “potential to develop into full human personhood” and thus he supports 
“human pre-embryo research, including research that produces and studies cloned human pre-
embryos through the 14th day of fetal development.” Human blastocysts from which ES cells are 
obtained are usually day-5. The only recommended limitations were that the embryos be treated 
respectfully, not be implanted, and that there is public discussion of the current and future 
research (Cole-Turner, 2000). Thus, the Christian faith seems to be divided on their views about 
embryonic stem cell research, but the majority believes it to be immoral. They only all support 
the usage of adult stem cells as a community. 
 
Judaism Ethics 
A more liberal ethical stand on stem cell research is that of Judaism. A main theological 
certainty of this faith is that they accept “both natural and artificial means for overcoming 
illness” and that doctors are both “the agents and partners of God in the ongoing act of healing” 
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(Dorff, 2000).  It is Jewish belief that they “have a duty to God to develop and use any therapies 
that can aid us in taking care of our bodies, which ultimately belong to God” (Dorff, 2000).  The 
Union of Orthodox Jewish Congregations stated that, “an isolated fertilized egg does not enjoy 
the full status of personhood” (Religious Views…2001). In fact, some Jews believe that 
‘ensoulment’ is not achieved until the moment of birth.  So, while it is wrong to unnecessarily 
abort a fetus, it cannot be considered murder.  However, an abortion is permitted if carrying the 
child is a threat to the mother’s health, or if the fetus is “severely defective” or has a terminal 
illness (Dorff, 2002).  In fact, due to Judaism’s emphasis on protecting and healing the body, “an 
abortion must be performed to save the life or the physical or mental health of the woman, for 
she is without question a full-fledged human being with all the protections of Jewish law, while 
the fetus is still only part of the woman’s body” (Dorff, 2002). 
With respect to the Jewish stance on when life begins, Rabbi Yehiel Ben Ayon confirmed 
that “Judaism teaches that life begins at birth; hence the possibility to kill life can only begin at 
the same time as that life begins” (Ayon, 2002).  In Judaism, an unborn child is not life but 
potential life.  Certainly an unborn child may not be aborted without a valid reason, but to do so 
is not killing. “It is forbidden, but it is not killing” (Ayon, 2002).  Dr. Rabbi Elliot N. Dorff, of 
the University of Judaism, explains that “Genetic materials outside the uterus have no legal 
status in Jewish law, for they are not even a part of a human being until implanted in a woman’s 
womb, and even then, during the first 40 days of gestation, their status is ‘as if they were simply 
water’” (Dorff, 2000).   
Therefore, Jewish law and religious beliefs allow for embryonic stem cell research. They 
also believe that the use of adult stems “is always accepted and even welcomed” (Ayon, 2002).  
Rabbi Yehiel Ben Ayon continues that “Judaism does not see the artificial growth of human cells 
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on a laboratory dish as a human life” and that “it is routine in medicine today to grow human 
skin for use in skin grafts. Growing stem cells should then be seen in the same light” (Ayon, 
2002). These quotes show that followers of Judaism believe that embryonic and adult stem cell 
research is moral and should be encouraged, as long as it is done for the common good.   And the 
embryo from which the stem cells are isolated must be aborted legitimately under Jewish law if 
abortion is the source. They also support the use of excess embryos from IVF procedures, as 
embryos formed outside of a woman’s body have an even lower status than those in the first 40 
days of gestation (Dorff, 2002). The subject of creating embryos specifically for research 
purposes is more difficult. Some feel that this should never be permissible, while others believe 
that it can be permitted under the condition that the woman only does this once or twice in her 
life due to the increased risk of developing ovarian cancer from drugs causing hyper-ovulation 
(Dorff, 2002). 
 
Islamic Ethics 
Islamic beliefs are based on textual information, mainly the Qur'an, without a major 
religious institution to guide the opinions of the followers. There are two schools of thought, the 
Sunni and the Shi`ite.  The Sunni make up the majority of Islamic followers, and interpret the 
text in a more traditional way than the Shi`ite (Sachedina, 2000). Both sects believe that they 
have an obligation serve society by using the knowledge that was given by God to help the 
common good (Frazzetto, 2004).  
There are many ideas about when the embryo reaches moral status. A majority of 
Muslims believe that after the blastocyst stage, the fetus becomes a person; ensoulment occurs 
120 days after conception (Frazzetto, 2004).  The Shari'ah text goes further to make “a 
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distinction between actual and potential life, determining that the former should be afforded 
more protection than the latter. Under most interpretations, the embryo is therefore not 
considered to be a person, and using it to create stem cell lines would not violate Islamic law” 
(Frazzetto, 2004).  Hassan Hathout, of the Islamic Organization for Medical Sciences in Kuwait, 
is quoted by Bill Broadway saying that “Islam opposes creating embryos with the intention of 
using them for research” (Broadway, 2001). However, Dr. Abdulaziz Sachedina of the 
University of Virginia explains that “it is correct to suggest that a majority of the Sunni and 
Shi`ite jurists will have little problem in endorsing ethically-regulated research on stem cells that 
promise potential therapeutic value, provided that the expected therapeutic benefits are not 
simply speculative” (Sachedina, 2000).  It would be easy to presume that both Islamic sects 
would support the use of adult stem cells, since no life is destroyed in the process of cultivating 
them.  
There is also Muslim disagreement over who could use the stem cells, as there is a great 
emphasis “on inter-human and familial relationships” (Frazzetto, 2004).  Giovanni Frazzetto 
explains that “the preservation of the parent−child lineage is of utmost importance to Muslims, 
as are the spousal relationships that encourage parental love and concern for their children.  Dr. 
Abdulaziz Sachedina explains further that “The Muslim focus of the debate on genetic 
replication and embryonic manipulation is concerned with moral issues related to the possibility, 
through these technologies, of creating incidental relationships between a man and a woman 
without a spiritual and moral connection between them” (Frazzetto, 2004). 
Consequently, Islamic law prohibits surrogate parenting and adoption, but would allow “the 
adoption of human embryos,” when excess embryos exist, for research purposes as long as they 
are used only by the couple who created them (Frazzetto, 2004).  
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The Islamic method of forming an opinion about controversial matters is ijtihad, where a 
panel of “qualified Islamic scholars” reviews current research, and through careful consideration 
decides on a position that conforms to Muslim belief (The Islamic Institute, 2001).  This panel 
decided that stem cell research should proceed. 
 
 
iPS (Induced Pluripotent Stem Cell) Ethics 
iPS cells are adult somatic cells (usually skin fibroblast cells) genetically modified by the 
integration of up to four transcription factors genes (or their proteins) into the adult cell genome 
(N.B., 2008).  Human iPS cells were first induced in 2007 in Yamanaka’s lab in Japan 
(Takahashi et al., 2007).  These cells do not involve risk of egg donors, nor does it destroy a 
human embryo or egg.  The exact level of potency of iPS cells is still being investigated, but 
some scientists argue they may be as potent as embryo-derived ES cells.  iPS cells even promise 
to correct numerous life threatening and disabling conditions.  If  iPS cell potency is pluripotent 
(or lower) most religious experts would accept the use of these cells as being similar to working 
with adult stem cells, as no embryos are destroyed. 
But if iPS cells are ever shown to be totipotent, the ethics changes considerably, and 
many ethicists realize that the issues posed by these cells would be as “thorny” as ever 
(Lehrman, 2010).  According to Francoise Baylis, an expert ethicist on ESC research and iPS 
cells, “there are some concerns which do not completely solve the ethical issues regarding iPS 
cells” (Brind’Amour, 2009).   In an online article entitled "ES Cells and iPS Cells: A Distinction 
with a Difference" for the Hastings Center in March of 2008, Baylis said that if iPS cells 
eventually demonstrate totipotency, which is required for the generation of a new human life, 
they would essentially be human embryos, and this generation would negate any advantage iPS 
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cells may have over ESCs in terms of the destruction of early human life (Baylis, 2008).  As of 
now, these cells haven’t even been able to be manipulated to grow the outer layer of an 
embryonic cell required for the development of the cell into a human being (Brind’Amour, 
2009).  Michael Rudnicki, scientific director of the Stem Cell Network, agrees and says the 
promise of stem cell advances using iPS cells is staggering.  He also notes "If iPS cells can be 
made safe for clinical therapies, it will ultimately make the delivery faster and more economical. 
But as a scientist I am cautious. So, much is based on future prospects and there is much work 
that needs to be done in the labs before it becomes a therapeutic reality” (University of Alberta, 
2009).  
If proven to be totipotent, in fertility clinics, iPS cells could enable prospective parents to 
choose embryos for desired traits more easily than they can with conventional assisted-
reproduction technologies. The possibilities would raise radical questions about the moral status 
of human cells, said Jan Helge Solbakk, the head of research at the Center for Medical Ethics at 
the University of Oslo in Norway, and Chair of the society’s Ethics and Public Policy 
Committee. 
One major concern regarding iPS cells is privacy; it is impossible to maintain donor 
privacy if the donor only provides a skin cell to the process. This is because to study the cells or 
to treat diseases such as Parkinson’s, juvenile diabetes or Alzheimer’s, it is necessary to know 
the donor’s health history and personal information (Sally Lehrman, 2010).  Another similar 
problem is that the ethical norms of consent and withdrawal may not be feasible. What if 
someone doesn’t want his/her tissues to be used for studies that involve the combination of both 
human and animal cells?  The cells will be growing worldwide, so it won’t be possible nor will it 
be fair for the donor to ask for the cells to be destroyed (Lehrman, 2010).  However, other 
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scientists disagree, reminding us that iPS cell lines would be used to treat the patient that 
provided the skin cell nucleus, not other patients, as the latter would reject the transplanted cells. 
Timothy Caulfield, research director of the Health Law Institute at the University of 
Alberta in Edmonton has noted “We have to recognize all the complicated issues that iPS 
research is engaging, and get a sense of how existing laws and policies play out” (Lehrman, 
2010). 
 
Chapter-3 Conclusion 
The proponents of stem cell research argue that the time for “modern medicine” has 
arrived.  Medical science to date has not cured many types of diseases, but stem cell therapies 
offer new hope.  It is time to look towards regenerative medicine to hopefully get the job done.  
The opposition would say that medical science is here to save lives not take them.  
All five major world religions support the use of adult stem cells, so long as they are used 
to save lives. Unfortunately these cells are harder to identify, harder to grow, and do not have the 
pluripotency of ES cells, but the authors of this IQP strongly support the use of adult stem cells 
whenever possible. 
ES cells have been chosen by scientists to treat the bulk of diseases for two main reasons. 
The first reason is their ability to differentiate into almost any of the approximate 220 types of 
cells. Adult stem cells can differentiate into only about six types of cells at best. Those six types 
of cells are limited to neuronal activity and the blood (Weiss, 2005), although more are being 
discovered all the time. The second reason is that ES cells are much easier to culture and isolate 
than adult stem cells. Adult stem cells are scarcer in the body and, therefore, harder to identify 
and isolate. 
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The scrutiny that scientists have had to endure over this subject is enough to drive anyone 
insane. It is hard for the author of this report to envision how anyone could stand in front of 
someone and tell them that you don’t think it is ethical to destroy embryos that have been 
fertilized on a lab bench while forgetting about the millions of existing lives that can be saved?  
How can someone call scientists murderers for destroying a cell mass barely visible, that has no 
brain or feeling, while condemning adult patients to death?  By shutting down ES cell research, 
isn’t it possible that some administrations are the bigger murderers. Too many times, people have 
a tendency to think about the present when it should be time to think about the future. 
It is comforting to see that people are starting to warm up to the idea of hES cell research. 
In a recent poll taken in Boston, MA from June 6 to June 12, 2005, sixty-seven percent of the 
residents polled said they were in favor of using taxpayer money to fund stem cell research. 
Forty percent said they were strongly in favor (Wallace, 2005).  The poll had reached only 405 
residents of the Hub, but this is at least an indication that the people of this country are slowly 
being educated on this subject. It wouldn’t be too surprising to find out that those who protest 
this subject know very little about the details involved with stem cell research, especially adult 
stem cell research. 
 It is not just Boston who has started to learn about stem cells.  Wisconsin senator Scott 
Fitzgerald tried to push for a ban in Wisconsin and at the University of Wisconsin-Madison on 
stem cell research, but was denied on both accounts (Still, 2005). There is even a recent push in 
the House of Representatives for federal funding of stem cell research; one vote in May 2005, 
was 238 to 194 in favor of federal funding for stem cell research.  When such bills reached 
former President Bush’s desk, they were vetoed, but not with President Obama.   
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The author of this chapter believes it is acceptable to work with either ES cells or adult 
stem cells, although adult stem cells should be favoured for a particular disease if shown to be 
equally effective.  With respect to embryo sources, the author believes excess IVF embryos 
created for reproductive purposes should be used first, and if those become exhausted paid 
donors may be used.   We must do everything in our power now to prepare for the future. Who 
knows how many of us may soon develop a fatal disease.   
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CHAPTER-4: STEM CELL LEGALITIES 
Divya Panickar 
 
 
However beneficial stem cell research may be, people cannot make use of this 
technology without setting rules and regulations to prevent misuse.  Stem cell laws are tied in to 
embryo laws, and vary greatly from country to country. In making these laws, legislators must 
take into account where the stem cells are collected from, who funds the research, and what the 
definition of a human being is (Stem Cell Laws, 2005).  So a particular country’s laws on stem 
cells often reflect political and religious issues within that country.  In this chapter, we discuss 
stem cell laws in specific countries and in the different states of the US.  
 
Stem Cell Laws and Funding in Different Countries 
Different countries have different policies mandating the level of stem cell and embryo 
research work that can be performed (Figure-1). Some countries permit almost all kinds of stem 
cell research, including human embryonic stem (ES) cell research, others are flexible about the 
extent of research work permitted (depending on the sources of funding and embryos), others 
completely restrict human embryonic stem cell research, and other countries completely lack any 
stem cell policies.  
Countries that permit ES cell research or therapeutic cloning (dark brown in the figure) 
include Australia, Belgium, China, India, Israel, Japan, Singapore, South Korea, Sweden, and the 
United Kingdom.  These countries represent more than 2.7 billion people.  Countries that do not 
permit therapeutic cloning but allow research on excess embryos no longer needed for 
reproduction (light brown in the figure) include Brazil, Canada, France, Iran, South Africa, 
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Spain, The Netherlands, Taiwan, the USA, and others.  Countries that outright prohibit human 
embryo research and permit limited research on only imported stem cell lines (yellow in the 
diagram) include Austria, Germany, Ireland, Italy, Norway and Poland (Hoffman, 2005). 
 
                 
                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: World Stem Cell Map. Map denotes the various countries 
relative to their stem cell policies. Color code: n-Permissive n-Flexible n-
Restrictive.  Countries allowing human embryonic stem cell research 
represent 3.8 billion people.  (Hoffman, 2005) 
 
 
Some of the legislations are influenced by religious or ethical values in the respective 
countries. Many opponents, including some religious leaders, believe that stem cell research 
raises the same moral issues as abortion, declaring that life begins at conception, so destroying a 
5-day embryo is murder.  Some laws have been amended to allow experiments on special types 
of induced pluripotent (iPS) cells since researchers in Wisconsin and Tokyo announced that they 
had transformed ordinary human skin cells into those that appeared to have the same properties 
as embryonic stem cells (Vestal, 2008). 
 58 
In Canada, stem cell research was restricted to adult stem cells until recently when new 
legislation permitting a small amount of human ES cell research was passed (Ebbin, 2007). 
Various Canadian institutes, including the government and health charities, fund the research but 
the largest source of funding is the Canadian Institute of Health Research (Ebbin, 2007). 
           Great Britain is the leader in ES cell research and has been for years because of their 
effective regulation, which appears to instill trust between scientists and the public. In the 1980s, 
Parliament organized a committee to address ethical concerns and research limitations.  From 
that committee came the formation of the Human Fertilization and Embryology Authority in 
1990.  This organization controlled what scientists and doctors did with research and therapeutic 
applications, and instilled public confidence that the embryos and research are put to use for the 
better of mankind and not being misused in the wrong hands (Berroth, 2009).  In Britain, the 
promise of societal good has always won out over ethical discomfort when it comes to embryo 
research. A few countries like Spain and Japan are developing their own stem cell banks, but 
Britain has taken the lead and its bank is likely to become a prototype, if not a resource, for the 
world.  To support stem cell technologies, the British government spent $ 4.7 million to create 
the stem cell bank that would store all the embryonic stem cell lines in Britain and would be 
monitored by a British ethics panel (Rosenthal, 2004). 
Israel was able to become a leader in ES research because they had the ability to tackle 
ethical, political, and regulatory issues early on.  Israeli stem cell research is strictly regulated 
with requirements for publishing and peer-reviewing. Scientist and researchers must go before a 
committee to state an intent in research to gain permission for further study. They are also not 
permitted to pay for a woman’s eggs or use research to clone a human being.  Israel allocates 
public and private funds for stem cell research regulated by Israeli law (Berroth, 2009). 
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The Swiss Parliament is considering the possibility of allowing research on stem cells 
derived from stored excess embryos remaining at the end of assisted reproduction procedures if 
they were frozen at seven or fewer days of development. This legislation is notable because the 
Swiss Constitution strictly prohibits research using human embryos and even sets controls over 
the number of eggs that may be fertilized and developed outside a woman’s body during fertility 
treatments. If the Swiss legislation passes, the thousands of frozen embryos of the nation would 
become available to researchers (Garfinkle, 2004). 
China is the ‘land of opportunity for stem cell research’. This is mainly due to its relaxed 
government laws regulating stem cell research. Since the Chinese culture has few religious or 
moral objections to the use of embryonic stem cells, the government has no qualms with funding 
this research for academic, educational, or therapeutic purposes. Although China may offer low 
barriers to stem cell research, it may come at the cost of risks of protecting intellectual property 
(IP).  Enforcement of IP protection laws is still weak in China compared to Western countries. 
These laws are also unclear since Chinese biotech companies are partially supported by 
government-owned universities and research centers. Incidents of plagiarism and falsified results 
in Chinese researchers’ work have been known to occur recently. Until China seriously addresses 
such issues, it will continue to sacrifice its competitive edge in the field of stem cell research 
(Barnes, 2006). 
Japan pioneered the creation of induced pluripotent stem (iPS) cell technology.  This was 
done at Kyoto University in Japan (Takahashi et al., 2006; 2007).  Japan is now ramping up 
patent efforts to keep this iPS lead since the United States might be the first to commercialize 
this technology.  On the same day that Kyoto University’s Shinya Yamanka reported his human 
iPS cells, James Thomson’s team at the University of Wisconsin-Madison separately published 
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similar results.  In Japan and Europe, the patent is awarded to the researchers who file first, while 
in the US the patent goes to the group that can show it invented the technology first.  Even 
though many researchers around the world give Yamanaka’ 2006 work on iPS cells in mice the 
credit for being the starting point of the whole field, the race for the patent still continues 
(Cyranoski, 2008).  Japan’s guidelines, set in 2001 for stem cell research have done great 
damage to related research fields in Japan. The guidelines allowed Japanese scientists to derive 
new human ES cell lines, and research both homegrown and imported cell lines, but only after 
the specific research was approved. The big issue was the approval.  Proposed projects had to be 
approved twice: first by a local institutional review board and then by a science-ministry 
committee. This resulted in only a quarter of the projects getting approval. Many Japanese 
researchers believe that although Yamanaka created iPS cell technology, the US stole the lead in 
iPS cell research since they did not have guidelines like in Japan that hindered further research. 
However, the Japanese government has been slowly trying to change the restrictions. New 
regulations were recommended by the Council for Science and Technology Policy, chaired by 
the prime minister.  The latest guidelines remove the secondary approval step for working with 
ES cells.  Now, only a local review committee must approve the work.  But it might be too late 
to make a difference since most of the Japanese researchers have been pushed into iPS research 
through targeted funding programs and are unlikely to return to ES cell basics (Cyranoski, 2009). 
Germany along with Austria, Poland, Slovakia, Lithuania, Luxembourg, and Malta are 
against the notion that the European Union (EU) should provide money for projects in some 
countries when the same research is prohibited in other member states.  However, European 
Research Commissioner Janez Potocnik said that research funding should not rely on the ethical 
standards of either the most restrictive or the most liberal countries since it would be against the 
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principles of the EU.  Laws on stem cell research vary largely across Europe with Germany 
enforcing a near total ban while the UK encourages it.  A 2006 survey also showed that 59% of 
Europeans approved of the research, provided there was government oversight on the projects 
(Deutsche, 2006).  International and European stem cell networks such as EuroStemCell and 
ESTOOLS had tried to convince the German parliament of the high potential of stem cell 
research and the impact of legislations in facilitating such research. By adopting four submitted 
proposals to amend the ‘Act ensuring the protection of embryos in connection with the 
importation and utilization of human embryonic stem cells' with 346 out of 580 votes, the 
Bundestag (lower house of parliament) changed the future of German stem cell research. The 
general ban on creating and working on human embryonic stem cell lines was upheld, however 
Germany will still be able to import cell lines harvested prior to a cut-off date.  The cutoff date 
was moved to 1st May 2007 from 1st January 2002.  The Bundestag have also amended the scope 
of the Stem Cell act, which refers to the utilization of human embryonic stem cells in Germany 
and the work of German scientists abroad as not constituting a criminal offence (Herman et al., 
2008). 
 
USA- The Leading Publisher of Articles on Stem Cell Research 
The US is currently by far the leader in stem cell research.  The US publishes about 3.5 
times as many stem cell articles as its nearest competitor Japan (Figure-2).  But many US 
scientists fear that it is slowly slipping behind countries like the UK, Korea, Singapore, Sweden, 
Israel, Australia and China, due to the political changes in its policies under the past several 
administrations.  
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Figure-2: Top Five Ranking Countries in Stem Cell Research Based on 
the Number of Research Articles Published.  The graph shows the number 
of research articles published by five countries over a period of 12 years. 
According to the graph, France is ranked 5th, UK 4th, Germany 3rd, Japan 2nd 
and the USA 1st based on the number of research articles published 
(Couffignal-Szymzcak, 2009). 
 
US Historical Embryo Policies 
Historically in the US, the stem cell policies have reflected which administration is in 
power (Figure-3).  In 1973, the US government refused to fund ES cell research after abortion 
was legalized (Roe v Wade, 1972); this step was taken to discourage women from having 
abortions for research purposes.  In 1993, when Bill Clinton became President, he formed the 
NIH Embryo Research Panel who recommended allowing some types of research on embryos 
created by IVF, but in 1995 the US Congress enacted the Dickey-Wicker Amendment that banned 
all embryo research (Robertson, 2010).  In spite of a 2000 NIH Guideline recommendation to 
allow some forms of embryo research, in 2001 President George Bush continued the Dickey-
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Wicker Amendment and banned all embryo research, although he allowed federal funding on ES 
cell lines established before 2001.    
In 2005, Congress passed the Stem Cell Research Enhancement Act, allowing the federal 
funding of new ES cell lines, but it was vetoed by Bush.  In that same year, the National 
Academy of Sciences also published their Guidelines for Human Embryonic Stem Cell Research 
(amended in 2007, 2008, and 2010), which was ignored by Bush.  In 2007, Congress passed the 
Stem Cell Research Enhancement Act, but it was again vetoed by Bush (Robertson, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3: Stem Cell Research Timeline in the US.  The figure shows a 
timeline of the progress of embryonic stem cell research in the US.  Shown 
are when Bush announced the ban in 2001 and when Obama lifted it in 
2009 (Genetics, 2009) 
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The ban on federal funding for ES cell research under Bush and the Dickey-Wicker 
Amendment drove most US embryonic stem cell research and IVF research into the private 
sector (Wertz, 2002).  In a Washington Post-ABC News poll conducted in January, 59% adults 
were in support of relaxing the restrictions on federal funding for ES cell research, and even 40% 
of Republicans supported reversing the ban.   In 2007, private funding in the US exceeded 
funding from the federal government (Ebbin, 2007).  
 
Current US Embryo Policies 
On March 9, 2009, President Obama lifted the eight-year-old ban, allowing federal 
funding for some types of embryonic stem cells, so long as scientists work with the 
approximately 61 ES cell lines already existing in the US.  This means private fertility clinics 
and research centers are now eligible to receive billions of dollars of federal funding (Wilson, 
2009).  President Obama issued a presidential memorandum aimed at insulating the scientific 
decisions across the federal government from political influence. He also made it clear that 
human cloning would still not be permitted.  Obama argued that the US has been falling behind 
in stem cell research because of the ban, and now that the ban has been partially lifted, he hopes 
that the US will play a leading role in exploring stem cell research frontier (Scadden, 2009).  To 
some in Congress, it remains unclear whether Obama actually overturned the earlier Dickey-
Wicker amendment that banned embryo research, so this issue has occasionally come into view.   
Obama’s policy was based on guidelines set by the National Institutes of Health (NIH) 
on embryonic stem cell research. The new guidelines explain which cell lines can be used in 
federally funded experiments. Some researchers were unhappy that the NIH did not recommend 
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allowing embryos for research purposes outside IVF clinics, allow somatic cell nuclear transfer 
(cloning), and allow parthenogenesis (from an unfertilized egg) (Holden, 2009). 
 
 
Legislations in the Different US States 
Especially important in the decade in which federal funding was banned for deriving new 
ES cell lines, individual states approved bonds to fund their own stem cell institutes.  Seven big 
states are leading the world in political and financial support for ES cell research (Figure-4). 
They aim to get the best scientists from all over the world and become the hub for a multi-
billion-dollar bioscience project.   
 
 
 
 
 
 
 
 
 
 
Figure-4:  2009 Policies in Various US States on ES Cell Funding.  The 
figure explains which states in the US fund stem cell research, which ensure 
legality but don’t fund research, and which ban research (Vestal, 2009). 
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In the past two years alone, California, Connecticut, Illinois, Maryland, New Jersey, New 
York and Wisconsin have awarded $230 million in grants.  California is the bellwether with a $3 
billion fund of taxpayer dollars being spent so far for research purposes (Figure-5). When all 
seven states’ investments are totaled, a sum of nearly $5 billion over the next 10 years is 
obtained.  Massachusetts has voted to add another $1 billion. Two other states, Iowa and 
Missouri, do not fund the research but have affirmed the legality of the research hoping to 
encourage scientists to work within their borders.  Some states like Arkansas, Indiana, Louisiana, 
Michigan, North Dakota, and South Dakota have voted to ban embryonic stem cell research, and 
Arizona bars state funding for embryonic studies (Vestal, 2008).  
 
 
 
 
 
 
 
 
 
 
 
Figure-5:  2008 ES Cell Research Funding by Different US States.  
The figure shows the amount of money funding ES cell research in 2008 
different states.  Such funding shows how the laws in specific states can 
over-ride the lack of federal funding in that state (Katz and Walker, 
2008). 
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In 2004, New Jersey became the first state in the US to support stem cell research, 
allocating $10 million to be distributed over 10 years to university, non-profit and commercial 
labs in the states.  Lawmakers have since allowed another $15 million for grants, and $9.5 
million to cover administrative costs of the program. California voters quickly followed the path 
of New Jersey in 2004 by approving a 10-year $3 billion funding program. This program became 
embroiled in legal proceedings over patent issues, but after the funding stalled, former Gov. 
Schwarzenegger gave the program a state loan of $150 million in 2006. However, the state 
almost ran out of money in 2009 because the state’s fiscal crisis and problems in the financial 
markets prevented it from issuing bonds.  Connecticut Gov. Rell signed a measure in 2005 to 
provide $100 million in state funding over 10 years for embryonic stem cell research. Illinois 
Gov. Blagojevich directed their public health department in 2005 to grant $10 million from 
existing public health funds to stem cell projects over 10 years, and added $5 million more to the 
fund after 2006 after Bush vetoed a bill seeking to open up federal funding for the science.  In 
2007, Maryland Gov. Ehrlich also signed a measure in 2006 appropriating $15 million in general 
funds.  The following year, first–term Gov. Malley appropriated another $23 million to be 
distributed in 2008. New York Gov. Spitzer signed a budget measure in 2007 that set aside $600 
million for stem cell research over 11 years. Wisconsin Gov. Doyle created a $750 million 
investment fund, including public and private money to build a research facility where 
embryonic stem cell studies would be conducted.  
With respect to Massachusetts, in 2005, the state legislature passed an act enhancing 
regenerative medicine in the commonwealth (An Act, 2005), but it was vetoed by then governor 
Mitt Romney.   On May 15, 2007, Governor Deval Patrick announced his one billion dollar plan 
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to fund life sciences including stem cell research in the state (Estes, 2007), which was signed in 
2008 (Life Science Bill Signing, 2008). 
Some states do not fund ES cell research but do not specifically ban it. Michigan voters in 
2008 approved a constitutional amendment making all forms of embryonic studies approved by 
the federal government legal in the state.  Iowa Gov. Culver signed a bill in 2007 repealing a 
2002 ban on the studies, and ensured the legality of all forms of stem cell research approved by 
the federal government (Vestal, 2009). 
With respect to other forms of research, federal funding of research involving cloning for 
the purpose of reproduction or research is strictly prohibited.  The Food and Drug Administration 
has claimed authority over the regulation of human cloning technology as an investigational new 
drug (IND) and stated that at this time, they would not approve any projects involving human 
cloning for safety reasons (Johnson, 2005), and in 2009 Obama banned human cloning.     
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PROJECT CONCLUSIONS 
 
 
 
 Based on the research performed in this project, the authors now make their own 
conclusions on the topic of stem cells.  The author of Chapters 1 and 3 believes that it is 
acceptable to work with ES cell lines, since stem cell therapies offer new hope to treat previously 
incurable diseases.  The author of Chapters 2 and 4 also believes that ES cell lines should be 
used, since it is high time people accepted this new promising technology. Both authors also 
strongly support the use of adult stem cells whenever possible, as there are lesser controversies 
surrounding their use.  However adult stem cells are harder to identify, isolate, and grow. The 
author of Chapters 1 and 3 also has a hard time questioning the destruction of a 5-day old 
embryo fertilized on a lab bench when millions of existing lives could be saved. The author of 
Chapters 2 and 4 believes that the embryo that is being destroyed for research purposes does not 
go through any pain and suffering since it doesn’t have a developed brain or nervous system.  
However, the destruction of embryos should be used only until a better source of producing 
pluripotent cells has been developed, such as iPS cells.  Both authors think iPS and ASCs should 
be used in countries where religious and ethical views have caused a ban in using ES cell lines 
for research. Both the authors, however, slightly differ in their opinion regarding having paid 
donors as the source of embryos. The author of Chapters 1 and 3 believes that excess IVF 
embryos created for reproductive purposes should be used first and if those become exhausted, 
paid donors may be used. The author of Chapters 2 and 4, on the other hand, believes that donors 
should not be paid, embryo donation should be allowed but purely on a voluntary basis, mainly 
to discourage frequent egg donations which may harm the woman.  Many people might misuse 
donor money in third world countries to force women to donate eggs or to get an abortion to 
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make money.  Both authors are in favor of using excess IVF embryos originally created for 
reproductive purposes for research with donor consent.  Countries like the UK, USA, China, 
India, Israel, Sweden and Japan are countries that have strong government regulated stem cell 
policies to prevent embryo misuse, while allowing scientists some freedom to perform research. 
Finally, both the authors conclude that all types of stem cell experiments should be permitted, 
other than cloning. 
 
